Raptor Pharmaceuticals Corp. (NASDAQ:RPTP)

CAPS Rating 5 out of 5 
RPTP VS S&P 500 (SPY)

RPTP News and Commentary

How do you think RPTP will perform against the market?

Motley Fool CAPS is a community working together to find better stocks and to become better investors.
Powered by: CAPS

All Players

26 Outperform
1 Underperform
 

All-Star Players

7 Outperform
0 Underperform
 

Wall Street

5 Outperform
0 Underperform
 

Top RPTP Bull/Bear Pitches

bassman87 (< 20)
Submitted November 22, 2010

Has a solid pipeline of products that should be advancing into phase 3 stage of FDA approval and beyond through the next 12 to 36 months. Most notable of all its products currently in phase 2 stage of development, is the drug Convivia. It is the only… More

zzlangerhans (99.67)
Submitted December 07, 2011

Raptor has sneakily crossed back above my red thumb threshold in the absence of new positive catalysts. The DR Cysteamine NDA won't be filed until Q1 2012 which means we won't be seeing any revenue numbers until at least 2013. I think the traders who… More

Featured Broker Partners


Advertisement